Proteoglycan-Induced Arthritis and Recombinant Human Proteoglycan Aggrecan G1 Domain–Induced Arthritis in BALB/c Mice Resembling Two Subtypes of Rheumatoid Arthritis

Tibor T. Glant, Marianna Radacs, Gyorgy Nagyeri, Katalin Olasz, Anna Laszlo, Ferenc Boldizsar, Akos Hegyi, Alison Finnegan, and Katalin Mikecz 
Source: Rheumatology
Publication Date: (2011)
Issue: 63: 5
Research Area:
Cells used in publication:
T cell, mouse, stim
Species: mouse
Tissue Origin: blood
Culture Media:


Objective. To develop a simplified and relatively inexpensive version of cartilage proteoglycan–induced arthritis (PGIA), an autoimmunity model of rheumatoid arthritis (RA), and to evaluate the extent to which this new model replicates the disease parameters of PGIA and RA. Methods. Recombinant human G1 domain of human cartilage PG containing “arthritogenic” T cell epitopes was generated in a mammalian expression system and used for immunization of BALB/c mice. The development and progression of arthritis in recombinant human PG G1–immunized mice (designated recombinant human PG G1–induced arthritis [GIA]) was monitored, and disease parameters were compared with those in the parent PGIA model. Results. GIA strongly resembled PGIA, although the clinical symptoms and immune responses in mice with GIA were more uniform than in those with PGIA. Mice with GIA showed evidence of stronger Th1 and Th17 polarization than those with PGIA, and antimouse PG autoantibodies were produced in different isotype ratios in the 2 models. Rheumatoid factor (RF) and anti–cyclic citrullinated peptide (anti-CCP) antibodies were detected in both models; however, serum levels of IgG-RF and anti-CCP antibodies were different in GIA and PGIA, and both parameters correlated better with disease severity in GIA than in PGIA. Conclusion. GIA is a novel model of seropositive RA that exhibits all of the characteristics of PGIA. Although the clinical phenotypes are similar, GIA and PGIA are characterized by different autoantibody profiles, and the 2 models may represent 2 subtypes of seropositive RA, in which more than 1 type of autoantibody can be used to monitor disease severity and response to treatment.